In this study, we analysed 30 patients with B-cell chronic lymphocytic leukaemia (CLL), compared with 10 healthy donors, for the expression and function of the leukocyteassociated Ig-like receptor-1 (LAIR-1). LAIR-1 is an inhibitory receptor containing a cytoplasmic tyrosine-based inhibitory motif (ITIM) that binds to the SH2 domain of phosphatases, leading to dephosphorylation of different kinases. Constitutive activation of c-Jun aminoterminal kinase (JNK), p38 mitogenactivated protein kinase and extracellular signal-regulated kinase, has been reported in CLL. We show that LAIR-1 is absent in high-risk (HR) CLL and differently expressed on intermediate-and low-risk CLL and the intensity of expression, which is always significantly lower than in healthy donors, correlates with disease stage and progression. Interestingly, both constitutive and sIgM-induced phosphorylation of p38 and JNK is inhibited by LAIR-1 through an ITIM-dependent signal, as demonstrated by the use of specific ITIM-binding peptides; importantly, this inhibitory signal is missing when LAIR-1 is not expressed as occurs in HR CLL. Moreover, engagement of LAIR-1 blocks constitutive and sIgM-induced Akt phosphorylation, besides nuclear factor j-B nuclear translocation, and prevents CLL division. These results suggest that CLL lacking LAIR-1 may miss one of the molecular mechanisms controlling B-cell activation and proliferation.
Introduction
The progressive accumulation of mature B lymphocytes, in the absence of a sizeable fraction of proliferating cells, has led to the assumption that B-cell chronic lymphocytic leukaemia (CLL) is in part related to defective apoptosis. [1] [2] [3] Overexpression of antiapoptotic genes, such as Bcl-2, deficiency of the proapoptotic Fas pathway and sustained activation of Akt and nuclear factor k-B (NF-kB) proteins have been implied in regulating the life of leukaemic B cells. [3] [4] [5] [6] Within the past decade, CLL has been considered as a disease primarily related to the delivery of survival signals from microenvironment to leukaemic cells. 7 Moreover, signalling molecules involved in cell-cycle progression, including extracellular signal-regulated kinase (ERK), c-Jun aminoterminal kinase (JNK) and p38 mitogen-activated protein kinase (p38MAPK), were found to be constitutively activated in CLL, [6] [7] [8] raising the possibility that an altered regulation of cell proliferation might also contribute to the leukaemic process and leading to ask if 'negative' or anti-proliferative signals might be involved as well.
Among the transmembrane molecules possibly involved in the delivery of negative signals, recent data point to members of the immunoglobulin superfamily, whose cytoplasmic tail contains immune receptor tyrosine-based inhibitory motifs (ITIM): upon engagement of the extracellular portion of the molecule, cytoplasmic ITIM bind to the SH2 domain of phosphatases (SHP), leading to inactivation of different kinases and downregulation of cell activation. [9] [10] [11] One of these receptors, the leukocyte-associated Ig-like receptor-1 (LAIR-1), 12 has been shown to inhibit monocyte function and differentiation, 13, 14 T-cell receptor-mediated and interleukin 2-dependent proliferation of T and natural killer (NK) cells, respectively. 15, 16 We reported that LAIR-1 engagement can inhibit proliferation of myeloid cells and acute myeloid leukaemia blasts induced by growth factors in vitro, by preventing NF-kB nuclear translocation, and that this effect is dependent on the ITIM of LAIR-1. 17, 18 Leukocyte-associated Ig-like receptor-1 is expressed also on B lymphocytes where it downregulates B-cell receptor (BCR)-mediated calcium mobilization; 19 interestingly, recruitment of SHP-1 has been shown to regulate ERK, p38 MAPK and JNK activation in chicken and murine B-cell lines. [20] [21] [22] [23] In turn, a link between p38 MAPK, JNK or ERK activation and NF-kB nuclear translocation has been described in a murine B lymphoma cell line. 24 In this paper, we show that: (i) LAIR-1 is mostly absent in highrisk (HR) CLL and differentially expressed in intermediate-risk (IR) and low-risk (LR) CLL and the intensity of expression relates to the stage of disease: (ii) constitutive and BCR-mediated activation of p38 and JNK is inhibited by LAIR-1 through an ITIM-dependent signal that is missing in HR CLL; (iii) when the molecule is expressed, engagement of LAIR-1 blocks Akt and NF-kB activation and prevents CLL division.
Materials and methods

Patients
Thirty untreated patients with CLL were studied. All the patients provided IRB-approved informed consent, at the Clinical Hematology Division (Department of Hematology and Oncology, University of Genoa). The patients met the diagnostic criteria of the National Cancer Institute Working Group (NCI-WG) 25 and were staged according to the Rai modified criteria 26 as LR, IR and HR. Their clinical features and risk factors are summarized in Table 1 . Ten healthy donors, matched for sex and age, were also studied. Progressive disease is defined as a change in the clinical features (that is, from LR to IR or from IR to HR or from LR to HR). 32 
Monoclonal antibodies and reagents
The phycoerythrin (PE)-conjugated anti-CD38 (IgG1), the PE-conjugated anti-CD19 (IgG1), the fluorescein isothiocyanate (FITC)-conjugated and the anti-CD20 (IgG2b) monoclonal antibodies (mAbs) were purchased from BD Pharmingen Europe (Milan, Italy); the Alexafluor 488-conjugated anti-Zap70 (IgG1) mAb was from CALTAG Laboratories (Burlingame, CA, USA). Goat anti-mouse Ig (GAM), the purified anti-human sIgM and murine Ig were from Sigma Chemicals Co. (St Louis, MO, USA) and recombinant interleukin 2 was from Pepro Tec EC (London, UK). The PE-or Alexafluor 647-conjugated anti-isotype GAM and the carboxy-fluorescein diacetate succinimidyl ester (CFSE) were from Invitrogen Molecular Probes Europe BV (Leiden, NL, USA). The anti-ICAM-1 (CD54) (14D2D12, IgG1) mAb and the anti-LAIR-1 mAb (NKTA255, IgG1) were purified by affinity chromatography.
14 The SHP-1-binding peptide, spanning the Tyr233-Tyr263 region of the cytoplasmic tail of LAIR-1, 15 
VTYAQLDHWALTQRTARAVSPQSTKPMAESITYAAV
(LAIR1pep), or the scrambled peptide VAATDRWSYKPQETQAL-SHAYRMALTIVATSAQLVT (LAIR-1pepM) were obtained from PRIMM (Milan, Italy) and used at the concentration of 10 mg ml
À1
. 18 
Isolation of B cells and proliferation assay
Peripheral blood mononuclear cells (PBMCs) were isolated from CLL patients or healthy donors by density gradient centrifugation 29 Ig mutation were evaluated as described. 29 In most patients CLL were sIgM + with the exception of patients 5,7,13,22,26 that were sIgD + . The sequences with a germ line homology 98% or higher were considered unmutated and those with a homology less than 98% mutated. 27,30 i Zap70 cytoplasmic expression was evaluated by immunofluorescence as described in materials and methods and was considered positive (Pos) when detected on 420% of B cells according to reported data. ), respectively, for 20 min at 4 1C, followed by GAM (10 mg ml
À1
) added during the test at 37 1C. For co-cross-linking, primary antibodies (NKTA255 and anti-sIgM) were added together at the beginning of the test, followed by GAM. In some experiments, the SHP-1-binding peptide (LAIR-1pep) or the scrambled peptide (LAIR-1pepM) were added at 37 1C 20 min, before cross-linking to allow the peptides to enter the cell. 18 Proliferation of CLL to anti-sIgM or anti-LAIR-1 was evaluated after labelling of PBMCs with CFSE at the beginning of culture; cells were then seeded into 96 U-bottom well plates (10 5 cells well À1 ). Recombinant interleukin 2 (25 U ml À1 ) was added on day 2, and cells were harvested on days 5, 7, 10 and 14, stained with PE-anti-CD19 to identify B cells, and analysed by flow cytometry.
Immunofluorescence and cytofluorometric analysis of CLL phenotype and proliferation Single or double immunofluorescence on PBMC of healthy donors and CLL patients was performed using the various mAbs, either FITC or PE conjugated or followed by PE-GAM. 29 Cytoplasmic staining for LAIR-1 or Zap70 was performed as previously reported, and this method has been validated by using a semiquantitative western blotting. 33 Control aliquots were stained with PE-FITC-or Alexafluor-labelled isotypematched irrelevant mAbs. To verify whether LAIR-1pep and LAIR-1pepM were entering the cell, FITC-labelled peptides (10 or 1 mM) were added to CLL for 20 min at 37 1C; in some samples, CLL were double stained with the anti-CD20 mAb, followed by Alexafluor 647-GAM, and analysed by confocal microscopy with a IX81-FV500 inverted microscope with a PlanApo objective Â 60 oil NA1.40 (Olympus Europe GMBH, Hamburg, Germany). For flow cytometry, samples were run on a flow cytometer (FACScan, Becton Dickinson, Franklin Lakes, NJ, USA) equipped with an argon ion laser exciting FITC and PE at 488 nm and gated to exclude non-viable cells. Data were analysed using CellQuest computer programme and are expressed as Log red fluorescence intensity (arbitrary units, a.u.) vs Log green fluorescence intensity (a.u.) or vs number of cells or as mean fluorescence intensity (MFI, a.u.). For proliferation assays, results are expressed as percentage of dividing B cells, identified by gating red cells (PE-anti-CD19) with decreased green fluorescence intensity (CFSE). Markers were set up on CFSE-labelled resting B cells. Data were analysed with the Modfit computer programme (ModFitLT version 3.0 Verity Software House, Topsham, MEUSA). Data presented refer to day 7 of culture, the time point where the maximal levels of cell division were observed.
Assay for the measurement of kinase activation
Activation of p38, MAPK kinase, JNK and Akt was assessed by the Searchlight Human Phosphorylated Kinase Assay (PIERCE, Rockford, IL, USA) on lysates of B lymphocytes from healthy donors or CLL patients. Lysates were obtained before or 10 min after cross-linking of sIgM and/or LAIR-1, in the presence or absence of LAIR-1pep or LAIR-1pepM, diluted 1:4 in the kinasebinding buffer and seeded into the assay plates following the manufacturer's instructions. The time point was chosen on the basis of preliminary kinetics experiments to detect optimal kinase activation. The assay is a multiplex sandwich ELISA for the quantitative measurement of p38, ERK, JNK and pSerAKT, developed with a chemiluminescent substrate and read with a cooled CCD camera (TEMA Ricerca, Milan, Italy). Results, elaborated by the ArrayVision software (Imaging Research Inc., GE Healthcare, Baie d'Urfe, Quebec, Canada) and compared to standard curves for each kinase, are expressed as pg per ml per 10 6 cells of activated kinase for p38, ERK, JNK and ng per ml per 10 6 cells for pAKT.
Transcription factor activation assay
Nuclear factor k-B activation was evaluated by the TransAM Assay Kit in nuclear extracts, obtained using the Nuclear Extract Kit (Active Motif, Rixensart, Belgium) from B lymphocytes from healthy donors or CLL patients, before or 12 h after cross-linking of sIgM and/or LAIR-1, in the presence or absence of LAIR-1pep or LAIR-1pepM. The time point was chosen on the basis of preliminary kinetics experiments to detect optimal NF-kB activation. TransAM NF-kB Kit is a 96-well plate with immobilized oligonucleotide containing the NF-kB consensus site (5 0 -GGGACTTTCC-3 0 ) that specifically binds to the active form of NF-kB contained in cell extracts. Primary antibodies directed against an epitope on p65 or p50 accessible only when NF-kB is activated, and bound to its target DNA, are then added, followed by horseradish peroxidase-conjugated secondary antibody; the reaction was developed by the specific substrate contained in the commercial kit. Plates were then read with and ELISA reader and results expressed as OD 450 nm .
Determination of mutational status of IgV H genes
The analysis of IgV H genes' mutational status was performed on cDNA as described previously. 29 After determining the IgV H gene family used by leukaemic cells, the V H gene sequences were determined by amplifying cDNA by PCR using the appropriate sense V H leader primer in combination with the appropriate antisense C H primer. The PCR products were sequenced directly after purification with PRC Preps (Promega, Madison, WI, USA) using an automated DNA sequencer (Applied Biosystems, Foster City, CA, USA). Sequences were compared to those present in the V BASE sequence directory (http://www.mrc-cpe.cam.ac.uk/imt-doc/vbase-home-page.htlm) and in the IMGT/V-QUEST database (http://imgt.cines.fr). 27 Results are expressed as percentages of germline homology. 27, 30 Statistical analysis Data are presented as mean±s.d. Statistical analysis was performed using analysis of variance, calculating the F ratio and, when corrected, applying the Bonferroni-Dunnett test with an a ¼ 0.05; w 2 analysis was also performed to correlate LAIR-1 MFI or percentage of LAIR-1 þ B cells with CD38 or Zap70 expression or IgV H genes mutational status.
Results
LAIR-1 is differentially expressed in HR, IR and LR CLL and relates to disease stage
Peripheral blood mononuclear cells from 30 CLL patients (10 HR, 10 IR and 10 LR) and 10 healthy controls were analysed for
the expression of LAIR-1 by immunofluorescence. Table 1 shows the clinical and phenotypic features of the cases studied. We found that, in all healthy donors, LAIR-1 was expressed on the surface of CD20 þ B lymphocytes, with a MFI ranging between 600 and 900 a.u. (Figure 1a , one representative case; Figure 1f ). On the contrary, the expression of LAIR-1 in CLL B cells was overall lower (MFIo500 a.u.), and the intensity of expression seemed to be related to the stage of disease. Activation of p38 and JNK in LAIR-1 þ CLL is inhibited by LAIR-1 engagement
To investigate the functional significance of the differential LAIR-1 expression in CLL, we tried to understand whether its engagement could lead to a regulation of kinase activation (that is, phosphorylation) and cell proliferation. As ERK, JNK and p38 MAPK were reported to be constitutively activated in CLL, [6] [7] [8] [9] we assessed their phosphorylation on lysates of B lymphocytes from CLL patients ( Figure 2 ) compared with healthy donors (Figures 2a and 3 ). Lysates were obtained before or after co-cross-linking of LAIR-1 (LAIR-1-XL) and of sIgM (sIgM-XL, with the exception of patients 05, 07, 13, 22 and 26 that were 
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A Poggi et al sIgM negative (sIgM À )) to study the effect of LAIR-1 engagement on kinase phosphorylation and on BCR-mediated signal. We found constitutive phosphorylation of ERK/MAPK kinase, p38 and JNK in B cells from all CLL patients (Figure 2a ). Upon sIgM cross-linking, both p38 and JNK phosphorylation could be upregulated in CLL; although to a lesser extent, MAPK kinase and ERK phosphorylation were also enhanced by sIgM engagement (Figure 2a) .
LAIR-1 engagement led to the downregulation of constitutive and sIgM-induced phosphorylation of p38 and JNK in CLL (Figures 2b and c) and to the inhibition of sIgM-driven activation of p38 and JNK in healthy donors (Figures 3a and b) . This mechanism was not operating in the HR patients who were LAIR-1 À , while an inhibitory effect was observed in two HR CLL expressing, although at very low levels, LAIR-1 (Figure 2d ). The inhibitory effect exerted by LAIR-1 on MAPK kinase and ERK phosphorylation was detectable (10% inhibition) although not statistically significant (data not shown). No effect, either in inducing or in inhibiting kinase activation, was observed with a mAb matched to anti-LAIR-1 for the isotype, directed to ICAM-1 and used as a negative control (Figures 2b and c; Figures 3a, b) . In some experiments, the SHP-1-binding peptide spanning the cytoplasmic functional ITIM of LAIR-1 (LAIR-1pep) or the scrambled peptide (LAIR-1pepM) were added 20 min before cross-linking to allow the peptides to enter the cell, as assessed by immunofluorescence and confocal microscopy or fluorescence-activated cell sorting analysis (Figure 4) . 18 Interestingly, the SHP-1-binding peptide could prevent the inhibition of constitutive and sIgM-induced activation of p38 and JNK observed upon LAIR-1 oligomerization; this effect was specific as the scrambled peptide was not effective (Figures 2b and c;  Figures 3a and b) . These data suggest that LAIR-1-mediated inhibition of kinase activation is dependent on a signal delivered via ITIM, and this negative signal cannot operate when the molecule is not expressed on the cell surface.
LAIR-1 engagement in LAIR-1 þ CLL blocks Akt and NF-kB activation
Sustained activation of the Akt signalling pathway and of NF-kB has been reported in CLL. 6, 24, 34 In our experiments, Akt phosphorylation was measured on lysates of B lymphocytes from CLL patients (n ¼ 8 HR, n ¼ 9 IR, n ¼ 8 LR) compared with B lymphocytes from healthy donors (n ¼ 10). As shown in Figure 5a , Akt is constitutively phosphorylated in all HR CLL; a lower, but significant Akt activation was observed in IR CLL, compared with LR CLL and healthy controls ( Figure 5a ). As shown in Figure 5b , Akt activation was inducible by sIgM oligomerization in IR and LR CLL. Of note, Akt was inhibited upon cross-linking of LAIR-1 in two HR CLL that express the molecule, but not in LAIR-1 À HR CLL ( Figure 5c) ; a similar inhibiting effect on constitutive Akt activation was observed in IR CLL (not shown). Again, the SHP-1-binding peptide, but not the scrambled peptide, added before LAIR-1 cross-linking could prevent this inhibition (Figure 5c ). It is of interest that statistical analysis showed an inverse correlation between LAIR-1 intensity of expression (MFI) and Akt constitutive activation in HR CLL (Po0.0001).
In parallel experiments, NF-kB activation (that is, nuclear translocation) was evaluated in nuclear extracts obtained from B lymphocytes of CLL patients (n ¼ 2 HR selected on the basis of 
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LAIR-1 expression, n ¼ 9 IR and n ¼ 8 LR, all LAIR-1 þ as shown in Figure 1 , selected on the basis of sIgM expression) or healthy donors (n ¼ 10) before or after cross-linking of sIgM and/or LAIR-1 (sIgM-XL and/or LAIR-1-XL). Some experiments were performed in the presence or absence of the SHP-1-binding peptide or the scrambled peptide as described previously. Figure 5 shows that NF-kB is constitutively translocated into the nucleus in CLL (d); of note, LAIR-1 engagement inhibits both constitutive and BCR-induced (sIgM-XL) NF-kB activation and this inhibiting signal is delivered via ITIM, as it is prevented by the specific peptide (Figure 5d ). In B cells of healthy controls, LAIR-1 is able to block the NF-kB activation due to sIgM oligomerization: also in this case, the inhibition is ITIMdependent, being prevented selectively by the SHP-1-binding peptide (Figure 5e ).
Engagement of LAIR-1 prevents cell division in
As the pattern of constitutive activation of kinases such as p38, JNK, Akt and of NF-kB is related to cell proliferation, we investigated the ability of LAIR-1-dependent inhibiting signal to interfere with cell division. To this aim, B cells from CLL patients (n ¼ 22: 8LR, 8IR, 2 LAIR-1 þ HR and 4 LAIR-1 À HR) or healthy donors (n ¼ 10) were cultured after BCR cross-linking (sIgM-XL): in some samples, CFSE-labelled PBMC underwent co-crosslinking of LAIR-1 (LAIR-1-XL) and sIgM at the beginning of the proliferation assay. In other experiments, the SHP-1-binding peptide (pep) or the scrambled peptide (pepM) were added before cross-linking. On day 2, recombinant interleukin 2 was added to the cultures. Based on preliminary kinetics experiments (not shown), on day 7 (maximal levels of cell division) cells were harvested, stained with the PE-anti-CD19 mAb to identify B cells and analysed by flow cytometry: results are expressed as percentage of dividing B cells, that is red (CD19 þ ) cells showing decreased green fluorescence intensity ( Figure 6 ). Interestingly, in CLL, sIgM-XL triggered the proliferation of CD19 þ B cells, which was strongly inhibited upon LAIR-1 engagement (Figure 6a , one representative experiment; Figure 6b , mean ± s.d. of experiments with cells from 19 CLL patients). The finding that LR CLLs display a proliferative response to sIgM cross-linking comparable to that of HR CLL, regardless of ZAP-70 expression, is apparently unexpected. However, this might be explained by the fact that CLL proliferation is thought to be mediated, at least in part, through Akt activation that we detected in LR CLL upon sIgM 
Results, compared to a standard curve, are expressed as ng per ml per 
Discussion
CLL is currently viewed as a malignancy where survival signals contribute to the accumulation of leukaemic cells together with a level of proliferation, which is likely higher than previously estimated. 7 Indeed, kinases involved in cell-cycle progression, including JNK and p38/MAPK, were found to be constitutively activated in CLL, [6] [7] [8] pointing to a defect in the regulation of B-cell proliferation. Probably, the lack or impairment of regulating surface receptors and sustained activation of cytoplasmic or nuclear factors act in concert to confer increased survival to CLL.
We propose that the lack of LAIR-1, which functions as an inhibiting molecule, could contribute to the defective regulation of CLL proliferation. Indeed, (i) constitutive and sIgM-induced phosphorylation of p38 and JNK is inhibited in CLL by LAIR-1; this inhibition is missing in LAIR-1 À CLL; (ii) engagement of LAIR-1 blocks Akt and NF-kB activation and prevents CLL division; (iii) LAIR-1 intensity of expression relates to kinase activation and to the stage of disease. LAIR-1 is known to deliver a negative signal due to the ITIM motif contained in its cytoplasmic tail, through the recruitment of SHPs and subsequent inactivation of intracellular kinases. [9] [10] [11] Herein, we have demonstrated that constitutive phosphorylation of p38 and JNK in CLL is inhibited by LAIR-1, when expressed at the cell surface, through an ITIM-dependent signal: indeed, a specific peptide spanning the ITIM domain that binds to the SH2 region of SHP1, completely abrogates the downregulation of p38 and JNK induced by LAIR-1 engagement in CLL. Besides the hyperactivation of these kinases, increased Akt phosphorylation has been reported to enhance survival and proliferative signals in leukaemic cells. [6] [7] [8] The magnitude of Akt signalling has been proposed to determine the distinct proliferative behaviour observed in leukaemic B cells belonging to the different prognostic subgroups. 6 Of note, we found that Akt is constitutively phosphorylated in HR and, to a significantly lesser extent in IR CLL, at variance with LR CLL where Akt was not activated, as well as in normal B lymphocytes; in LAIR-1 þ HR and IR CLL, LAIR-1 oligomerization leads to the inhibiting signal that cannot occur in CLL lacking LAIR-1, mostly HR. These data would suggest that LAIR-1 is linked to signalling pathways that, ultimately, contribute to the control of kinases involved in cell proliferation. Indeed, p38, JNK and Akt converge to the 
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A Poggi et al activation of transcription factors, such as NF-kB, which may lead to cell survival and proliferation. 5, 6, 24, 34, 35 We have previously reported that LAIR-1 can inhibit proliferation of acute myeloid leukaemia blasts induced by growth factors, by preventing NF-kB nuclear translocation, and this effect is ITIMdependent. 17, 18 Along this line, we observed that LAIR-1 engagement blocks both constitutive and sIgM-induced NF-kB activation in CLL. It is of note that in our experiments, engagement of LAIR-1 could also prevent proliferation of leukaemic B lymphocytes, which express the molecule through an ITIM-dependent negative signal. It has recently been reported that collagens are ligands for LAIR-1; 36 one can hypothesize that the binding of LAIR-1 to these ligands contributes in vivo to the control of the biochemical mechanisms, which lead to the activation of kinases involved in cell-cycle progression. This mechanism results impaired in neoplastic B cells lacking LAIR-1. Besides the level of Akt activation, the constitutive nuclear translocation of transcription factors has been proposed as hallmark of the disease stage in CLL patients. 6, 24, 25 Indeed, in our study, we confirmed that constitutive activation of both Akt and NF-kB is detectable mainly in B cells from HR CLL patients. Noteworthy, we found that LAIR-1 is differently expressed on HR and LR CLL, being absent on most HR CLL: this may provide an explanation for the lack of control of kinase activation, in particular Akt, mostly found in HR CLL. It is possible to hypothesize that the absence of LAIR-1 might confer, to a fraction of B cells, a mechanism of escape from the control of cell activation and proliferation. Nevertheless, when expressed, although at low levels of intensity, LAIR-1 could still provide CLL with a regulating signal.
From this viewpoint, it is of interest that among the patients analysed in this study, a relationship between LAIR-1 intensity of expression and disease stage and progression seems to be conceivable. First, LAIR-1 was absent in most HR CLL and very low on IR CLL, at variance with LR CLLs that display a higher LAIR-1 intensity of expression. Second, we found a correlation between LAIR-1 expression and two risk factors, CD38 or Zap70 expression. Moreover, we found a direct correlation between the unmutated state of IgV H and the absence of LAIR-1 at the surface of CLL. Along this line, during B-cell differentiation, LAIR-1 is lost in germinal centre B lymphocytes, where IgV H somatic mutations should take place, 7 whereas it is expressed in mutated memory B cells of the lymph node marginal zone. 19 Both subsets of CLL (unmutated and mutated) have been proposed to derive from memory B lymphocytes of the marginal zone. 7, 37 It is tempting to speculate that the lack of LAIR-1 identifies a fraction of CLL, of germinal centre origin, which underwent an inadequate encounter with the antigen. On the other hand, LAIR-1 þ mutated CLL would be derived from marginal zone antigen experienced B lymphocytes. It is still to be defined the mechanism underlying the altered LAIR-1 expression in CLL. Whatever is the origin of leukaemic B cells, our data would indicate that CLL lacking LAIR-1 might miss one of the molecular mechanisms controlling B-cell activation and proliferation, possibly representing a factor contributing to the survival of leukaemic B cells.
